Business Segments · R&D
Business Segments — R&D
Regeneron Pharmaceuticals Business Segments — R&D decreased by 5.1% to $1.54B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 16.3%, from $1.33B to $1.54B. Over 3 years (FY 2022 to FY 2025), Business Segments — R&D shows an upward trend with a 17.6% CAGR.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026
Rolls up toR&D
How to read this metric
An increase suggests a higher investment in the pipeline, which may lead to future growth but reduces current profitability. A decrease may indicate a shift toward commercialization or cost-cutting measures.
Detailed definition
This metric represents the total financial resources allocated to internal and collaborative research and development ac...
Peer comparison
Comparable to R&D expense segments in other large-cap biopharmaceutical firms, often benchmarked as a percentage of total revenue.
Metric ID:
regn_segment_reportable_segment_research_and_developmentHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $898.13M | $898.13M | $898.13M | $898.13M | $1.11B | $1.11B | $1.11B | $1.11B | $1.25B | $1.20B | $1.27B | $1.41B | $1.33B | $1.42B | $1.48B | $1.63B | $1.54B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +23.6% | +0.0% | +0.0% | +0.0% | +12.5% | -3.9% | +6.0% | +11.1% | -6.0% | +7.1% | +3.7% | +10.2% | -5.1% |
| YoY Change | — | — | — | — | +23.6% | +23.6% | +23.6% | +23.6% | +12.5% | +8.1% | +14.6% | +27.2% | +6.3% | +18.5% | +16.0% | +15.2% | +16.3% |
Range$898.13M – $1.63B
CAGR+14.5%
Avg YoY Growth+17.6%
Median YoY Growth+16.3%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's business segments — r&d?
- Regeneron Pharmaceuticals (REGN) reported business segments — r&d of $1.54B in Q1 2026.
- How has Regeneron Pharmaceuticals's business segments — r&d changed year-over-year?
- Regeneron Pharmaceuticals's business segments — r&d increased by 16.3% year-over-year, from $1.33B to $1.54B.
- What is the long-term trend for Regeneron Pharmaceuticals's business segments — r&d?
- Over 3 years (2022 to 2025), Regeneron Pharmaceuticals's business segments — r&d has grown at a 17.6% compound annual growth rate (CAGR), from $3.59B to $5.85B.
- What does business segments — r&d mean?
- The total amount of money spent on research and development activities to create new medicines.